Clinical Trials
FDA accepts new drug application, grants priority review for ALS treatment
Biogen Inc. announced that the FDA has accepted a new drug application for tofersen, an investigational drug to treat superoxide dismutase 1 ALS.
Phase 2 gene therapy trial for Stargardt disease underway
Cancer clinical trials recover from substantial disruption during COVID-19 pandemic
Oncology clinical trials appeared to recover from declines in enrollment and activation during the early phase of the COVID-19 pandemic, according to a study of data from two large academic centers published in Annals of Oncology.
Eptinezumab reduced migraine effects for adults with previous treatment failures
For adults with migraine and repeated preventive treatment failures, eptinezumab produced significant reductive effects compared with placebo, along with acceptable safety and tolerability, per a study published in Lancet Neurology.
FDA places hold on phase 2/3 clinical trial of stroke therapy
Biopharmaceutical company DiaMedica Therapeutics Inc. announced that the FDA placed a clinical hold on its phase 2/3 ReMEDy2 trial of a synthetic protein therapy for treatment of acute ischemic stroke.
NIH grants $45 million to study potential Alzheimer’s therapy in clinical trial
The NIH awarded a $45 million grant over 5 years to Burke Neurological Institute to evaluate benfotiamine, a synthetic precursor of thiamine, as a potential therapy for mild Alzheimer’s disease or mild cognitive impairment.
Dextromethorphan-bupropion effective in improving symptoms of major depressive disorder
Dextromethorphan-bupropion significantly improved symptoms for those with major depressive disorder compared with bupropion alone and produced minimal adverse effects, according to a study published in American Journal of Psychiatry.
uniQure releases promising data from phase 1/2 trial of Huntington’s disease gene therapy
Gene therapy company uniQure has announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing phase 1/2 clinical trial of AMT-130 for treatment of Huntington’s disease.
Continuous subcutaneous foslevodopa/foscarbidopa infusion shows promise in phase 3 study
Continuous subcutaneous infusion of foslevodopa/foscarbidopa was safe and improved motor complications in patients with advanced Parkinson’s disease, according to data presented at the European Academy of Neurology Congress 2022.
Neurona Therapeutics announces clinical trial for drug-resistant focal epilepsy treatment
Neurona Therapeutics has announced that a phase 1/2 clinical trial for NRTX-1001, a regenerative neural cell therapy for treatment of drug-resistant focal epilepsy in adults, is now underway.